We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-13.52%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$641M
AUM Growth
-$134M
Cap. Flow
-$30.9M
Cap. Flow %
-4.83%
Top 10 Hldgs %
43.19%
Holding
88
New
23
Increased
22
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
SKIN icon
SkinHealth Systems
SKIN
+$40.8M
2
ORGO icon
Organogenesis Holdings
ORGO
+$16.9M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$15.1M
4
ANAB icon
AnaptysBio
ANAB
+$14.3M
5
CUTR
Cutera, Inc.
CUTR
+$13.6M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$21.8M
2
OSUR icon
OraSure Technologies
OSUR
+$20.7M
3
HOLX
Hologic
HOLX
+$17.3M
4
SNN icon
Smith & Nephew
SNN
+$12.3M
5
TXG icon
10x Genomics
TXG
+$8.07M

Sector Composition

Rank Sector Weight
1 Healthcare 87.21%
2 Consumer Staples 6.57%
3 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.8M 1.37%
914,346
-50,130
-5% -$629K
PEN icon
27
Penumbra
PEN
$12.7B
$8.57M 1.34%
+68,800
New +$10.9M
PCVX icon
28
Vaxcyte
PCVX
$7.81B
$8.06M 1.26%
370,650
+42,300
+13% +$979K
IOVA icon
29
Iovance Biotherapeutics
IOVA
$1.82B
$7.94M 1.24%
+719,600
New +$9.43M
PVLA
30
Palvella Therapeutics
PVLA
$1.99B
$7.73M 1.21%
51,686
– –
STE icon
31
Steris
STE
$22.3B
$7.69M 1.2%
37,310
-3,950
-10% -$891K
SUPN icon
32
Supernus Pharmaceuticals
SUPN
$2.59B
$7.46M 1.16%
258,100
+7,100
+3% +$203K
CVRX icon
33
CVRx
CVRX
$137M
$6.37M 0.99%
1,059,040
+96,875
+10% +$557K
HZNP
34
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.21M 0.97%
+77,842
New +$7.37M
INCY icon
35
Incyte
INCY
$24.2B
$6.05M 0.94%
+79,700
New +$6.05M
TMDX icon
36
Transmedics
TMDX
$2.64B
$5.8M 0.91%
+184,455
New +$4.92M
EIGR
37
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.33M 0.83%
28,200
+2,100
+8% +$423K
STAA icon
38
STAAR Surgical
STAA
$1.21B
$5.33M 0.83%
+75,094
New +$4.84M
NARI
39
DELISTED
Inari Medical, Inc. Common Stock
NARI
$4.92M 0.77%
+72,298
New +$5.2M
FATE icon
40
Fate Therapeutics
FATE
$286M
$4.82M 0.75%
194,400
-11,500
-6% -$317K
ENTA icon
41
Enanta Pharmaceuticals
ENTA
$366M
$4.73M 0.74%
100,000
-102,485
-51% -$5.56M
EXAS
42
DELISTED
Exact Sciences
EXAS
$4.69M 0.73%
+119,000
New +$6.36M
NTRA icon
43
Natera
NTRA
$38.3B
$4.67M 0.73%
131,873
-23,127
-15% -$856K
RCKT icon
44
Rocket Pharmaceuticals
RCKT
$340M
$4.38M 0.68%
+318,100
New +$3.79M
ESTA icon
45
Establishment Labs
ESTA
$2.72B
$4.26M 0.67%
+78,400
New +$4.98M
INMD icon
46
InMode
INMD
$870M
$4.2M 0.66%
187,449
+40,949
+28% +$1.08M
PLRX icon
47
Pliant Therapeutics
PLRX
$64.4M
$3.92M 0.61%
490,000
+250,000
+104% +$1.6M
CCXI
48
DELISTED
ChemoCentryx, Inc.
CCXI
$3.83M 0.6%
+154,400
New +$3.4M
MIRM icon
49
Mirum Pharmaceuticals
MIRM
$6.46B
$3.81M 0.6%
196,018
-147,482
-43% -$3.48M
CELC icon
50
Celcuity
CELC
$4.21B
$3.81M 0.59%
418,912
+386,839
+1,206% +$2.83M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return

Soleus Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Soleus Capital Management held 88 positions worth $641M, down 17% from $775M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management withdrew a net $30.9M in Q2 2022, closing 16 positions and reducing 22 holdings. Its most notable exit was Illumina, an estimated $21.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 80% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Soleus Capital Management opened a new position in Tandem Diabetes Care worth $10.9M.

  • Soleus Capital Management's largest Q2 2022 buy was Tandem Diabetes Care: 183,800 shares worth $10.9M.
  • Soleus Capital Management added most to SkinHealth Systems in Q2 2022, an estimated $40.8M increase.
  • Soleus Capital Management's biggest Q2 2022 reduction was Kyntra Bio, cutting an estimated $7.79M.
  • Soleus Capital Management fully exited Illumina in Q2 2022, selling an estimated $21.8M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $641M portfolio in Q2 2022.
  • Soleus Capital Management opened 23 new positions and closed 16 in Q2 2022.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $641M.

Based on Soleus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.